Related Experiment Video
Updated: Apr 18, 2026

Multimodal Protocol for Assessing Metacognition and Self-Regulation in Adults with Learning Difficulties
Published on: September 27, 2020
Substance use disorders in individuals with mild to borderline intellectual disability: current status and future
Neomi van Duijvenbode1, Joanneke E L VanDerNagel2, Robert Didden3
1Radboud University Nijmegen, Behavioural Science Institute, P.O. Box 9104, 6500 HE Nijmegen, The Netherlands.
Abstract:
Knowledge regarding substance use (SU) and substance use disorder (SUD) in individuals with mild to borderline intellectual disabilities (ID) has increased over the last decade, but is still limited. Data on prevalence and risk factors are fragmented, and instruments for screening and assessment and effective treatment interventions are scarce. Also, scientific developments in other fields are insufficiently incorporated in the care for individuals with ID and SUD. In this selective and critical review, we provide an overview of the current status of SU(D) in ID and explore insights on the conceptualisation of SUD from other fields such as addiction medicine and general psychiatry. SU(D) turns out to be a chronic, multifaceted brain disease that is intertwined with other physical, psychiatric and social problems. These insights have implications for practices, policies and future research with regard to the prevalence, screening, assessment and treatment of SUD. We will therefore conclude with recommendations for future research and policy and practice, which may provide a step forward in the care for individuals with ID and SUD.
Related Concept Videos
Intellectual Disability
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Learning Disabilities
Dyslexia
Dyslexia is a...
CNS Depressants: Alcohol and Nicotine
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

